the injection that can be used to reduce weight, what are the side effects
Reading File
Finding Sources
Searching PubMed
GLP-1 agonist semaglutide weight loss side effects
Searching the Web
semaglutide tirzepatide weight loss injection side effects 2025
Reading File
Reading File
Here is a thorough breakdown of the injections used for weight loss and their side effects:
Weight Loss Injections - Side Effects
The main injectable medications approved for weight loss are GLP-1 receptor agonists (and the newer dual GIP/GLP-1 agonist tirzepatide). Here's what you need to know:
1. Semaglutide (Wegovy / Ozempic)
Mechanism: GLP-1 receptor agonist - slows gastric emptying, reduces appetite, and promotes satiety.
Common Side Effects (very frequent):
- Nausea - most common, especially during dose escalation
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain / bloating
- Decreased appetite (intended effect, but can be excessive)
- Fatigue / weakness
- Headache
- Heartburn / acid reflux
- Burping
- Vertigo / dizziness
Most GI side effects occur during dose increases and typically improve within 4-8 weeks as the body adjusts.
Serious but less common risks:
| Risk | Notes |
|---|---|
| Pancreatitis | Acute inflammation of the pancreas - seek emergency care for severe abdominal pain |
| Thyroid tumors / medullary thyroid cancer | Black box warning; contraindicated in personal or family history of medullary thyroid cancer or MEN type 2 |
| Gallbladder disease / cholecystitis | Rapid weight loss increases gallstone risk |
| Increased heart rate | Mild elevation in resting pulse |
| Suicidal ideation | Rare; monitor for mood changes |
| Acute kidney injury | Usually from dehydration secondary to vomiting/diarrhea |
| Injection site reactions | Redness, swelling, or bruising at injection site |
2. Tirzepatide (Zepbound / Mounjaro)
Mechanism: Dual GIP + GLP-1 receptor agonist - more potent weight loss than semaglutide alone (20.2% vs 13.7% weight loss in the head-to-head SURMOUNT-5 trial, NEJM 2025).
Side effects are similar to semaglutide but slightly more frequent:
- Nausea: ~43% (vs ~24% with semaglutide)
- Vomiting: ~48% (vs ~29% with semaglutide)
- Diarrhea: ~40% (vs ~21% with semaglutide)
- Anorexia: ~64%
- Weakness: ~41%
- Headache: ~14%
- Vertigo: ~26%
- Injection site reactions
3. Liraglutide (Saxenda)
Mechanism: GLP-1 receptor agonist (daily injection; older than semaglutide which is weekly).
Side effects per textbook (Fuster & Hurst's The Heart, p. 282):
- Nausea, vomiting, diarrhea, constipation
Contraindications:
- Pregnancy
- Personal/family history of medullary thyroid cancer
- MEN (Multiple Endocrine Neoplasia) type II
- Acute pancreatitis
- Acute gallbladder disease
Summary Table
| Side Effect | How Common | When It Occurs |
|---|---|---|
| Nausea | Very common (23-43%) | During dose escalation |
| Vomiting | Common (28-48%) | During dose escalation |
| Diarrhea | Common (21-40%) | Early treatment |
| Constipation | Less common (~2%) | Variable |
| Fatigue/weakness | Common (~42%) | Throughout treatment |
| Heartburn | Common (~47%) | Throughout treatment |
| Headache | Less common (~10-14%) | Variable |
| Pancreatitis | Rare (~1%) | Any time |
| Thyroid tumors | Very rare | Long-term |
| Gallbladder disease | Uncommon | With rapid weight loss |
Key Warnings
- Do NOT use if you have a personal or family history of medullary thyroid cancer or MEN type 2
- Stop and seek care for severe, persistent abdominal pain (possible pancreatitis)
- Pregnancy: All these medications are contraindicated in pregnancy
- Discontinuation: About 46.5% of patients stop GLP-1 injections within one year, often due to GI intolerance
- Muscle loss ("Ozempic body"): Rapid weight loss can cause loss of muscle mass - resistance exercise is recommended alongside these medications
Recent evidence confirms the overall safety profile: a 2025 systematic review in Annals of Internal Medicine confirmed GLP-1 agonists are effective for weight loss in non-diabetic adults, with GI adverse events being the primary reason for discontinuation. A 2024 meta-analysis in Obesity Reviews also confirmed the benefit-risk profile in post-bariatric patients.
Sources: Fuster & Hurst's The Heart (15th ed.), Yamada's Textbook of Gastroenterology (7th ed.), SURMOUNT-5 trial (NEJM 2025), real-world data (PMC12783929, 2025)
does it interfere with Brain function and attention, can hamper study?
Finding Sources
Searching PubMed
semaglutide GLP-1 cognitive function brain attention
Searching the Web
semaglutide GLP-1 brain fog cognitive effects attention concentration 2025
Searching PubMed
GLP-1 receptor agonist neurological effects brain neuroprotective
Reading Web Page
https://www.frontiersin.org/journals/aging-neuroscience/arti…
This is a genuinely interesting and important question, especially for students. Here is what the evidence actually shows:
Do Weight Loss Injections Affect Brain Function and Studying?
The Short Answer
Probably not harmful to cognition - and may actually be mildly beneficial in the long run. However, certain indirect effects of these medications can temporarily affect focus, energy, and study performance, particularly in the early weeks.
How GLP-1 Drugs Interact With the Brain
GLP-1 receptors are not just in the gut and pancreas - they are found throughout the central nervous system, including in areas that control:
- Appetite and reward (hypothalamus, nucleus accumbens)
- Memory and learning (hippocampus)
- Mood regulation
- Executive function (prefrontal cortex)
This means semaglutide and similar drugs are biologically capable of affecting thinking and attention - the question is whether the effect is positive, negative, or neutral.
What Research Shows
1. Brain Fog / Cognitive Slowing - Patient Reports
Many people report "brain fog" - a feeling of mental fuzziness, slow thinking, or difficulty concentrating. However:
- Brain fog is not listed as a confirmed side effect on the FDA label for semaglutide
- Clinical trials have not identified it as a direct drug effect
- It clusters in the first 4-6 weeks of dose escalation, then typically improves
- Most experts attribute it to indirect causes (see below)
2. Studies Leaning Positive - Improved Cognition
Multiple recent studies have found semaglutide is associated with better cognitive outcomes:
- A 2025 UK retrospective study (ECNP Congress, Amsterdam) found semaglutide was associated with improved memory and broad cognitive function in people with psychiatric disorders
- A 2025 RCT in HIV patients found semaglutide improved visuospatial abilities, language, and memory recall
- Animal studies show GLP-1 agonists reduce neuroinflammation, protect the blood-brain barrier, and increase BDNF (Brain-Derived Neurotrophic Factor) - a protein that supports learning and memory
- A 2025 review in Neurotherapeutics confirmed GLP-1 receptors have a significant role in neuroprotection
3. Mixed / Null Findings
- A Phase 2 RCT in Major Depressive Disorder found no improvement in executive function (the primary endpoint) with semaglutide, though some secondary cognitive domains showed trends
- In established Alzheimer's disease, clinical trials have so far shown no benefit
- The current evidence suggests effects may be population-dependent and more relevant as prevention than treatment
4. Psychiatric Side Effects (Real Signal)
A 2025 VigiBase pharmacovigilance study on dulaglutide, semaglutide, and liraglutide found reports of:
- Anxiety
- Depression
- Mood changes
- Sleep disturbances
These are rare but real signals from large-scale adverse event databases.
Why Students Might Notice Problems - Indirect Effects
This is the most likely explanation for study difficulties:
| Indirect Cause | How It Affects Study |
|---|---|
| Reduced caloric intake | The brain runs on glucose - eating too little causes fatigue and poor concentration |
| Nausea / vomiting | Hard to sit and study when feeling sick |
| Dehydration | Even mild dehydration impairs memory and focus significantly |
| Nutrient deficiencies | Reduced food intake can cause low B12, iron, zinc - all needed for brain function |
| Disrupted sleep | GI discomfort can interrupt sleep, which directly damages memory consolidation |
| Fatigue / weakness | Reported in ~42% of users - makes sustained mental effort harder |
| Reduced "food reward" motivation | GLP-1s blunt dopamine reward pathways (part of why they work) - this can temporarily reduce general motivation |
Practical Advice for Students
- Eat enough protein and calories - don't go too low; the brain needs fuel to study
- Stay well hydrated - aim for 2-2.5L of water/day, especially if nauseous
- Take a multivitamin - cover nutrient gaps from reduced food intake
- Dose escalation timing - if you can, increase doses during low-pressure periods (not exam week)
- Most symptoms improve within 4-6 weeks - if brain fog persists beyond that at a stable dose, speak to your doctor
- Track your symptoms - sudden or severe confusion is not expected; that needs medical evaluation
Bottom Line
The injections themselves do not directly damage cognitive ability - the biological evidence actually leans toward neuroprotection. The study difficulties people experience are mostly indirect, caused by nausea, fatigue, low calorie intake, and disrupted sleep, especially during early dose escalation. These are manageable and temporary for most people.
Sources: Frontiers in Aging Neuroscience (2026), Psychiatric Times / ECNP 2025, VigiBase pharmacovigilance study [PMID 40617160], Neurotherapeutics review [PMID 40738791], drugs.com medical review (2025)
This is a shared conversation. Sign in to Orris to start your own chat.